Chaperone-Based Therapies for Disease Modification in Parkinson's Disease

Area of Science:

• Neuroscience
• Molecular Biology
• Pharmacology

Background:

• Parkinson's disease (PD) is a prevalent neurodegenerative disorder linked to misfolded alpha-synuclein aggregates.
• Protein homeostasis (proteostasis) machinery, including molecular chaperones, is compromised in PD.
• Existing PD treatments do not halt disease progression, highlighting the need for new therapeutic avenues.

Purpose of the Study:

• To review the role of molecular chaperones in Parkinson's disease pathogenesis.
• To explore chaperone-based therapies as a disease-modifying strategy for PD.
• To summarize the potential of enhancing neuroprotective chaperone activity or using small molecule chaperones.

Main Methods:

• Literature review of preclinical and clinical studies on molecular chaperones in PD.
• Analysis of evidence for chaperone dysfunction in Parkinson's disease.
• Synthesis of current research on chaperone-modulating therapeutic approaches.

Main Results:

• Molecular chaperones are frequently downregulated, sequestered, depleted, or dysfunctional in PD.
• Chaperone dysfunction contributes significantly to the accumulation of toxic protein aggregates.
• Therapeutic strategies targeting chaperones show promise for enhancing proteostasis.

Conclusions:

• Modulating molecular chaperones and associated pathways presents a promising disease-modifying therapeutic approach for PD.
• Enhancing endogenous chaperone activity or employing small molecule chaperones could restore proteostasis.
• Chaperone-based therapies offer a novel strategy to address the underlying pathology of Parkinson's disease.